

**Neuralstem Inc. (CUR):** Neuralstem has a patented technology that according to the company enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Central nervous system diseases targeted by the Company include: Ischemic paraplegia, traumatic spinal cord injury, and ALS. The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets.